[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100371352":3},{"organization":4,"armGroups":7,"interventions":68,"overallOfficials":75,"centralContacts":80,"locations":85,"responsibleParty":110,"collaborators":74,"id":112,"slug":74,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":74,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":74,"enrollmentInfo":120,"targetDuration":74,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":141,"overallStatus":88,"whyStopped":74,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65],{"label":9,"type":10,"description":11,"interventionNames":12},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Pancreatic","EXPERIMENTAL","SMART will be administered per each individual disease site standards",[13],"Radiation: MR-guided Linac",{"label":15,"type":10,"description":11,"interventionNames":16},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Renal",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Central Lung",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Adrenal Metastases",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Liver Metastases",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Metachronous Oligometastatic Nodes",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Oligoprogressive Oligometastatic Nodes\u002FSoft Tissue",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Synchronous Oligometastatic Nodes\u002FSoft Tissue",[13],{"label":36,"type":10,"description":11,"interventionNames":37},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Prostate",[13],{"label":39,"type":10,"description":11,"interventionNames":40},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Borderline Resectable Pancreas",[13],{"label":42,"type":10,"description":11,"interventionNames":43},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Brain Metastases",[13],{"label":45,"type":10,"description":11,"interventionNames":46},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Mesothelioma",[13],{"label":48,"type":10,"description":11,"interventionNames":49},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Prostate Boost",[13],{"label":51,"type":10,"description":11,"interventionNames":52},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Pelvic Re-Irradiation",[13],{"label":54,"type":10,"description":11,"interventionNames":55},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Spine",[13],{"label":57,"type":10,"description":11,"interventionNames":58},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Single-Fraction Kidney Tumors",[13],{"label":60,"type":10,"description":11,"interventionNames":61},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--1\u002F3 Fraction for Oligometastatases in the Abdomen\u002FPelvis",[13],{"label":63,"type":10,"description":11,"interventionNames":64},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Post-Operative Radiation Therapy in Lung Cancer",[13],{"label":66,"type":10,"description":11,"interventionNames":67},"PHASE 1: SBRT MR IMAGE GUIDANCE\u002FADAPTATION--Mediastinal and Hilar Lymph Nodes",[13],[69],{"type":70,"name":71,"description":72,"armGroupLabels":73,"otherNames":74},"RADIATION","MR-guided Linac","Radiation will be delivered on an MR-guided Linear Accelerator",[60,21,39,42,18,24,66,45,27,30,9,51,63,36,48,15,57,54,33],null,[76],{"name":77,"affiliation":78,"role":79},"Jonathan Leeman, MD","Brigham and Women's Hospital","PRINCIPAL_INVESTIGATOR",[81],{"name":77,"role":82,"phone":83,"phoneExt":74,"email":84},"CONTACT","617-732-6452","JONATHANE_LEEMAN@DFCI.HARVARD.EDU",[86,102],{"facility":87,"status":88,"city":89,"state":90,"zip":91,"country":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"Brigham & Women's Hospital","RECRUITING","Boston","Massachusetts","02115","United States",{"type":94,"coordinates":95},"Point",[96,97],-71.05977,42.35843,{"lat":97,"lon":96},[100,101],{"name":77,"role":82,"phone":74,"phoneExt":74,"email":74},{"name":77,"role":79,"phone":74,"phoneExt":74,"email":74},{"facility":103,"status":88,"city":89,"state":90,"zip":91,"country":92,"cosmosGeoPoint":104,"geoPoint":106,"contacts":107},"Dana Farber Cancer Institute",{"type":94,"coordinates":105},[96,97],{"lat":97,"lon":96},[108,109],{"name":77,"role":82,"phone":74,"phoneExt":74,"email":74},{"name":77,"role":79,"phone":74,"phoneExt":74,"email":74},{"type":79,"investigatorFullName":77,"investigatorTitle":111,"investigatorAffiliation":5,"oldNameTitle":74,"oldOrganization":74},"Principal Investigator","100371352",false,"NCT04115254","Stereotactic Magnetic Resonance Guided Radiation Therapy","A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)","Inclusion Criteria:\n\n* Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.\n* Tumor size ≤ 7cm\n* Age 18 years of older.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Specific eligibility requirements for each disease site with be covered in each specific cohort.\n\nExclusion Criteria:\n\n* Specific exclusion requirements for each disease site with be covered in each specific cohort\n* History of allergic reactions attributed to gadolinium-based IV contrast.\n\n  \\-- Note: If a patient will not receive contrast, this is not applicable\n* Pregnant women are excluded from this study.\n* Severe claustrophobia or anxiety\n* Participants who cannot undergo an MRI","ALL","18 Years",{"count":121,"type":122},397,"ESTIMATED","INTERVENTIONAL",[125],"NA","This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.\n\n* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.\n* Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures",[128,129,130,131,132,133,134,135,136,137,138,139,140],"Pancreas Cancer","Lung Cancer","Renal Cancer","Adrenal Metastases","Prostate Cancer","Liver Metastases","Oligoprogressive Nodal Metastases","Metachronous Nodal Metastases","Synchronous Nodal Metastases","Mesothelioma","Spine Metastases","Brain Metastases","Borderline Resectable Pancreatic Carcinoma",[142,143,128,129,130,131,132,133,144,145,146,147,148,149],"Magnetic Resonance Imaging (MRI)","MRIdian Linear Accelerator","Oligoprogressive","Metachronous","Synchronous","Spine","Prostate Boost","Pelvic Re Irradiation","2025-11-11",{"date":152,"type":153},"2025-11-13","ACTUAL",{"date":155,"type":153},"2019-10-22",{"date":157,"type":122},"2028-06",{"name":5,"class":6},2]